776TiPGlobal phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress
ANNALS OF ONCOLOGY(2018)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
ANNALS OF ONCOLOGY(2018)